thesis

submit your research paper discussing treatments for crohn's disease

U.S. flag

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

  • Publications
  • Account settings

Trending Articles

  • Streptococcus anginosus promotes gastric inflammation, atrophy, and tumorigenesis in mice. Fu K, et al. Cell. 2024. PMID: 39461336 No abstract available.
  • Tobacco Smoke Plays an Important Role in Initiation and Development of Lung Cancer by Promoting the Characteristics of Cancer Stem Cells. Lu L, et al. Cancer Manag Res. 2020. PMID: 33116833 Free PMC article. Review.
  • Amino acid is a major carbon source for hepatic lipogenesis. Liao Y, et al. Cell Metab. 2024. PMID: 39461344
  • Global, regional, and national burden of injuries, and burden attributable to injuries risk factors, 1990 to 2019: results from the Global Burden of Disease study 2019. GBD 2019 Injuries Collaborators. Public Health. 2024. PMID: 39454232
  • Multi-omics landscape and molecular basis of radiation tolerance in a tardigrade. Li L, et al. Science. 2024. PMID: 39446960

Latest Literature

  • Am J Clin Nutr (1)
  • Cochrane Database Syst Rev (4)
  • J Immunol (2)
  • PLoS One (59)
  • Pediatrics (2)
  • Proc Natl Acad Sci U S A (23)

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

COMMENTS

  1. A review of the therapeutic management of Crohn’s disease

    Anti-TNF drugs are highly effective in the management of CD but treatment failure is a common downfall to these medications. The personalised anti-TNF therapy in Crohn’s …

  2. Novel and emerging drugs for the treatment of Crohn’s disease: a …

    We delve into the clinical efficacy and safety profiles of emerging therapies, encompassing JAK inhibitors, IL-23 inhibitors, anti-adhesion molecules, S1P1 receptor …

  3. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical …

    1. Introduction. Crohn’s disease [CD] is a chronic inflammatory bowel disease [IBD] that can result in progressive bowel damage and disability. 1 CD can affect individuals of …

  4. Mirikizumab: A promising breakthrough in Crohn's disease treatment

    By Week 12, mirikizumab significantly outperformed placebo in clinical response (45.4% vs. 19.6%, p < 0.000001). By Week 52, it showed higher clinical remission rates (54.1% vs. 19.6%) …

  5. Evidence-Based Approach to the Management of Mild …

    The guideline-based treatment recommendations for induction of remission of mild CD include a tapering course of ileal released budesonide vs a systemic corticosteroid taper for patients with ileal or proximal colonic …

  6. Therapy for Crohn’s Disease: a Review of Recent Developments

    The last several years have seen a number of exciting developments in the field of Crohn’s therapy. This review covers research advances including updated treatment …

  7. Novel and emerging drugs for the treatment of Crohn's disease

    We delve into the clinical efficacy and safety profiles of emerging therapies, encompassing JAK inhibitors, IL-23 inhibitors, anti-adhesion molecules, S1P1 receptor modulators, and combined …

  8. Comparative efficacy and safety of biologic therapies …

    We did a systematic review and network meta-analysis of phase 2 and phase 3 randomised controlled trials done in adults (≥18 years) with moderate-to-severe Crohn's disease (Crohn's Disease Activity Index [CDAI] …